October 1, 2021
Pharmaceutical manufacturers
Taro Pharmaceuticals USA, Inc.,
Sandoz Inc. and
Apotex Corporation have agreed to pay a total of $447.2 million to resolve alleged violations of the False Claims Act and Anti-Kickback Statute arising from unlawful compensation received through arrangements on price, supply and allocation of customers with other pharmaceutical manufacturers of various generic drugs. In connection with the FCA settlements, Taro will pay
$213.2 million, Sandoz will pay
$185 million, and Apotex will pay
$49 million. The civil settlements are in addition to previous deferred prosecution agreements resolving related criminal charges, pursuant to which Taro paid a criminal penalty of $205.6 million, Sandoz paid a criminal penalty of $195 million, and Apotex paid a criminal penalty of $24.1 million.
DOJ